RhoA 蛋白及驱动蛋白 Kif2A 与卵巢癌临床病理特征的相关性研究

目的??探讨 RhoA 蛋白和驱动蛋白 Kif2A 在卵巢癌组织中的表达及临床意义。方法??采用免疫组织 化学法检测正常卵巢组织 20 例、卵巢上皮良性肿瘤 25 例以及卵巢癌 45 例中的 Kif2A、RhoA 蛋白表达，观察 RhoA、Kif2A 在 3 组中的表达情况，分析其表达与临床病理特征的关系及两者间的相关性。结果??与卵巢上皮 良性肿瘤、正常卵巢组织比较，卵巢癌组织中 Kif2A、RhoA 蛋白的阳性表达率更高（ P <0.05） ； 正常卵巢组织 与卵巢上皮良性肿瘤间的表达比较差异无统计学意义（ P >0.05） 。卵巢癌分期、淋巴结转移与 Kif2A 蛋白的表 达密切相关（ P <0.05） ； 与组织学分级、病理类型以及年龄无关（ P >0.05） 。淋巴结转移、组织学分级与 RhoA 蛋白表达密切相关（ P <0.05） ； 与病理类型、临床分期以及年龄无关（ P >0.05） 。Kif2A、RhoA 在卵巢癌中 的表达呈正相关（ r =0.801， P <0.05） 。结论??Kif2A、RhoA 蛋白在卵巢癌组织中高表达 ； 两者可能共同参与 卵巢癌的发生、发展过程， 为临床靶向治疗卵巢癌提供新思路。

Clinicopathological significance of Kif2a and Rhoa in ovarian cancer

Objective To investigate the clinical significance of KiF2A and RhoA in ovarian cancer. Methods Totally 20 cases of normal ovarian tissues, 25 cases of benign epithelial ovarian tumors, and 45 cases of ovarian cancer were involved in this study. Expression of KiF2A and RhoA protein was identified by immunohistochemistry. Association between KiF2A/RhoA and clinicopathological features was analyzed. Results The positive rates of KiF2A and RhoA protein expression in ovarian cancer tissues were increased compared with those in ovarian epithelial benign tumors and normal ovarian tissues (P < 0.05), while no significant difference in expression of KiF2A and RhoA between normal ovarian tissues and benign epithelial ovarian tumors was confirmed (P > 0.05). Expression of KiF2A was closely correlated to ovarian cancer staging and lymph node metastasis (P < 0.05). RhoA was closely associated with lymph node metastasis and histological grading (P < 0.05). The expression of KiF2A was positively correlated to expression of RhoA in ovarian cancer (r = 0.801, P < 0.05). Conclusions High expression of KiF2A and RhoA proteins in ovarian cancer tissues may be involved in the development of ovarian cancer.